Over his fifty-year tenure at the Johns Hopkins School of Medicine, Dr. Griffiths dedicated years to investigating the effects of mood-altering substances, including opiates, cocaine, sedatives, alcohol, nicotine, and caffeine, on the human brain.
In 1999, Johns Hopkins University gave Dr. Griffiths the green light to resume research into the medical promise of psilocybin – a decision that catapulted the psychedelic medicines field.
Read our coverage here.
The two-day Oncology event will see industry experts from across the clinical trial space holding talks on subjects from AI to business
A pioneering study published in the International Journal of Molecular Sciences by researchers at Durham University has revealed promising results for a new treatment targeting
Issuer: CureVac / Key word(s): Study 20.06.2023 / 13:05 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Doses First Patient